Organization (Industry)
KURA ONCOLOGY, INC.
ClinicalTrials.gov lists KURA ONCOLOGY, INC. as lead sponsor of 17 trials. It has 78 active development programs and 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers KURA ONCOLOGY, INC.: 17 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (25)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 8 |
| Hematologic Neoplasms | 4 |
| Carcinoma, Squamous Cell | 3 |
| Head and Neck Neoplasms | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
Showing 5 of 25 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 4 |
| 2021 | 2 |
| 2019 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 1 |
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 8 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (78)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Ziftomenib | Leukemia, Myeloid, Acute | Phase 3 | 5 |
| Ziftomenib | Hematologic Neoplasms | Phase 3 | 4 |
| CYTARABINE | Hematologic Neoplasms | Phase 3 | 3 |
| CYTARABINE | Leukemia, Myeloid, Acute | Phase 3 | 3 |
| AZACITIDINE (VIDAZA) | Leukemia, Myeloid, Acute | Phase 3 | 2 |
Showing 5 of 78 active programs.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CYTARABINE | 3 |
| Daunorubicin | 2 |
| Venetoclax | 2 |
| AZACITIDINE (VIDAZA) | 2 |
| Alpelisib | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 63% hit target (n=8) | 0% on time (n=8) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Blood advances | 1 |
| Current opinion in hematology | 1 |
| Molecular cancer research : MCR | 1 |
| The Lancet. Oncology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 33 | 14 | 2025-11-11 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 67,482,000 | -278,666,000 | 251,074,000 |
| 2024 | 53,883,000 | -173,983,000 | 169,967,000 |
| 2023 | 0 | -152,631,000 | 115,235,000 |
| 2022 | not reported | -135,840,000 | 92,812,000 |
| 2021 | not reported | -130,466,000 | 84,721,000 |
| 2020 | not reported | -89,625,000 | 60,397,000 |
| 2019 | not reported | -63,140,000 | 47,826,000 |
| 2018 | not reported | -60,447,000 | 46,787,000 |
| 2017 | not reported | -35,434,000 | 26,426,000 |
| 2016 | not reported | -27,560,000 | not reported |
Showing 10 of 11 fiscal years.
Financing and grant events (29)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-12-02 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-10-24 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-06-05 | Other financing | not disclosed | Sec extracted |
| 2024-11-20 | Royalty / licensing | 330,000,000 | Sec extracted |
| 2024-02-15 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 29 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Mirati Therapeutics (United States) | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Mass General Brigham | Co sponsors trial with | 1 |
| The Pediatric Oncology Experimental Therapeutics Investigators' Consortium | Co sponsors trial with | 1 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (86)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-02 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-30 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2025-11-13 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
Showing 5 of 86 events.
Biomarker capability evidence (142)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| CD19 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 142 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.